Momelotinib in MF with anemia: Real-world findings

A summary of recent real-world datasets

Study 1 MOMGEMFIN: Patients with MF and anemia treated with momelotinib through a managed-access program across 74 centers in Spain[1]

N = 154

STUDY POPULATION

76.6% JAKi-experienced | **23.4%** JAKi-naïve

122 patients* were assessed for anemia response (median Hb level, 8.0 g/dl), 73.8% were TD.

Median FU **5.1 months**

SPLEEN AND SYMPTOM RESPONSE

62.2% **Spleen size reduction** n=45, patients with splenomegaly >5 cm at baseline. (24.4% met formal ELN response criteria)

92% **Sustained symptom improvement** n=134, patients with disease-related symptoms at baseline.

ANEMIA RESPONSE: TD PATIENTS



Median transfusion burden reduced from 4 to 1 RBC units/month.

Median Hb increased from 7.7 to 8.7 g/dL.

SAFETY

Thrombocytopenia, 10.3% (Grade 3–4, 6.2%); diarrhea, 11.7%; infections, 9.0%; hepatotoxicity, 5.6%; permanent discontinuation due to toxicity, 4%.

Study 2 A German retrospective chart review of hematologic outcomes with momelotinib in patients with MF and anemia[2]

N = 77

STUDY POPULATION

49% JAKi-experienced | **51%** JAKi-naïve

Primary or secondary MF and anemia (Hb <10 g/dL)

HB RESPONSE



Median Hb change from baseline to Week 24

Overall	+1.3 g/dL
JAKi-naïve	+1.6 g/dL
JAKi-experienced	+1.0 g/dL

50% of evaluable JAKi-naïve patients achieved an Hb increase ≥2 g/dL.

TRANSFUSION INDEPENDENCE



Among patients who were TD at baseline, 64% became TI by Week 24.

PLATELET RESPONSE

Platelet counts remained stable during treatment, including in patients with baseline thrombocytopenia (<100 × 10^9/L and <50 × 10^9/L).

Additional data from heterogeneous EU real-world cohorts further support clinically meaningful spleen and symptom responses alongside anemia benefit with momelotinib.[3–5]

In real-world settings, momelotinib has demonstrated meaningful improvements in spleen size, symptoms, and anemia, including high TI rates, with a manageable safety profile in patients with MF and anemia. Efficacy was observed in both JAKi-naïve and JAKi-experienced patients and results broadly reflect those observed in clinical trial populations, supporting its use in MF with anemia in routine practice.

ELN, European LeukemiaNet; EU, European Union; FU, follow-up; Hb, hemoglobin; IWG, International Working Group; JAKi, Janus kinase inhibitor; MF, myelofibrosis; ORR, overall response rate; RBC, red blood cell; TD, transfusion dependent; TI, transfusion independent.

1. Pérez-Lamas L, *et al*. *Blood Cancer* J. 2025;15(1):67. **2.** Al-Ali HK, *et al*. Abstract #PB3455.†
3. Chanut M, *et al*. Abstract #PB3432.† **4.** D'Agostino D, *et al*. Abstract #PB3517.† **5.** Vida EO, *et al*. Abstract #PB3537.†

*Met the 2024 IWG-ELN criteria for anemia. † Presented at: EHA 2026 Congress; Jun 11–14, 2026; Stockholm, SE.

MPNHub | Brought to you by SES

Intended for healthcare professionals. This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.